United States was Telix Pharmaceuticals’s largest region in fiscal 2025, bringing in $784.91M of $803.79M (98%).
| Geography | FY 2022 | FY 2025 |
|---|---|---|
| United States | $150.01M | $784.91M |
| China | — | $9.83M |
| Other Countries | $6.88M | $9.06M |
| United Kingdom | $2.05M | — |
| Belgium | $564.00K | — |
| Canada | $456.00K | — |
| Australia | $149.00K | — |
| Total | $160.10M | $803.79M |
Telix Pharmaceuticals brought in $803.79M from its three regions in fiscal 2025, the year ended December 31, 2025. Telix Pharmaceuticals regrouped these regions after fiscal 2022, so the total does not compare directly with that year's $160.10M. United States was the largest at $784.91M (97.7%), ahead of China at $9.83M (1.2%) and Other Countries at $9.06M (1.1%).
Telix Pharmaceuticals began breaking out China in fiscal 2025, when it brought in $9.83M. Telix Pharmaceuticals stopped reporting United Kingdom ($2.05M in fiscal 2022), Belgium ($564.00K in fiscal 2022), Canada ($456.00K in fiscal 2022) and one other as separate regions.
Telix Pharmaceuticals (TLX) reports its revenue by geography. In fiscal 2025, United States was its largest region, bringing in $784.91M (97.7% of the total), followed by China at $9.83M (1.2%).
United States was Telix Pharmaceuticals' largest region in fiscal 2025, bringing in $784.91M, or 97.7% of the $803.79M total across its three regions.
Every figure comes from Telix Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Telix Pharmaceuticals gives it, and years follow its fiscal calendar.
Telix Pharmaceuticals' revenue by geography goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.